Article

Article

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in HER2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–HER2 Therapy

March 30, 2023
Article

Integrating Technology and Expertise

February 21, 2022
Article

Sample Size Re-Estimation as an Adaptive Design

September 15, 2021
Article

Operational Characteristics of Generalized Pairwise Comparisons for Hierarchically Ordered Endpoints

September 2, 2021
Article

Immunotherapy Against Cancer: Challenge and Opportunities

August 4, 2021
Article

Drug Development in Oncology in the Era of Precision Medicine

June 29, 2021
Article

Clinical Development Trends

June 28, 2021
Article

Personalized Medicine: A Work in Progress

June 28, 2021
Article

The Importance of Early Phase Trials in Precision Oncology

June 28, 2021
Article

Considerations on the Mechanics and Sample Sizes for Early Trials of Targeted Agents and Immunotherapy in Oncology

June 28, 2021

When every data point represents a patient, accuracy and integrity aren’t optional — they’re everything. That’s why it’s IDDI.

Start Now